Business Wire

Uptime’s 13th Annual Global Data Center Survey Shows Widening Range of Challenges

18.7.2023 13:03:00 EEST | Business Wire | Press release

Share

Uptime Institute today announced the release of its 13th Annual Global Data Center survey. The findings show data center operators facing stricter regulations and more pressure to reduce energy, along with persistent staffing and supply chain issues. The Report shows new technologies potentially presenting a promising way forward, but these often are found lacking in standardization and scalability. While for many organizations, investments in efficiency and resiliency are beginning to pay off, progress has been gradual.

“Our data shows operators grappling with several issues,” said Andy Lawrence, executive director, Uptime Intelligence. “In 2023, the lingering effects of the COVID-19 pandemic have receded, but other challenges have emerged. Digital infrastructure managers are now most concerned with improving energy performance and dealing with staffing shortfalls, while Government regulations aimed at improving data center sustainability and visibility are beginning to require attention, investment, and action.”

Uptime’s Annual Global Data Center survey is the largest, most comprehensive, and longest-running study in the digital infrastructure sector. It provides detailed insights into the digital infrastructure landscape and a view into its future trajectory. Key findings from the 2023 report include:

  • Average global power usage effectiveness (PUE) levels have remained flat for four years. Additional improvements in PUE levels will require significant investment.
  • As more organizations opt for a hybrid approach to IT, the share of enterprise workloads that are run in corporate, on-premises facilities has fallen to below half for the first time and is expected to shrink further.
  • Enterprise operators say data security is the biggest impediment to moving mission-critical workloads to the public cloud. Resiliency and transparency are lesser concerns.
  • Server rack densities are climbing steadily, but slowly. Average rack densities are below 6 kilowatt (kW) per rack; most operators do not have any racks beyond 20 kW. This suggests the widespread use of direct liquid cooling is not imminent.
  • Many operators only collect a limited amount of sustainability related data and will struggle to meet emerging sustainability reporting requirements, or in turn, the requirements of some customers and the public.
  • Most operators believe acceptance of the use of artificial intelligence will grow in data centers, but operators are distrustful of its ability to make reliable operational decisions.

Outages:

  • More than half (55%) of operators reported they have had an outage at their site in the past three years, the lowest number yet recorded. This continues a trend of steady improvement.
  • Power outages continue to be cited as the single biggest cause of outages.

Staffing:

  • Uptime Intelligence data shows that approximately 8% of the data center workforce are women. In the US (if not all countries), this rate is below that of other male-dominated industries, such as mining and construction.
  • Nearly two-thirds of operators have problems recruiting or retaining staff – however, this figure is not currently growing. The largest skill gaps are in operations, mechanical and electrical roles.

About the Survey:

Uptime conducted this year’s annual Global Data Center Survey online from February – April 2023 and collected responses from more than 850 data center owners and operators and nearly 700 vendors and consultants.

Learn More:

Uptime’s 2023 Global Data Center Survey also includes findings on regulatory support, sustainability, and metrics, staffing shortfalls, skills gaps, diversity, innovation and impact, and more. Download the executive summary report here and register for the webinar covering its key trends and takeaways on July 18th at 12:00 PM EDT, 5:00 PM BST.

About Uptime:

Uptime Institute is the Global Digital Infrastructure Authority. For over 25 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. With its Tier Standard and Certifications, Management & Operations reviews, SCIRA-FSI financial sector risk assessment, broad range of additional risk and performance assessments, intelligence research service, and training courses completed by over 10,000 data center professionals, Uptime has helped thousands of companies in over 114 countries to optimize critical IT assets while managing costs, resources, and efficiency.

Uptime Institute is headquartered in New York, NY, with offices in London, Sao Paulo, Dubai, Riyadh, Singapore, and Taipei. For more information, please visit www.uptimeinstitute.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brenda South
206/706-4647
bsouth@uptimeinstitute.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye